Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Neurovirol ; 26(5): 734-742, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32500476

RESUMO

The purpose of this study was to assess whole brain and regional patterns of cerebrovascular reactivity (CVR) abnormalities in HIV-infected women using quantitative whole brain arterial spin labeling (ASL). We hypothesized that HIV-infected women would demonstrate decreased regional brain CVR despite viral suppression. This cross-sectional study recruited subjects from the Bay Area Women's Interagency Health Study (WIHS)-a cohort study designed to investigate the progression of HIV disease in women. In addition to conventional noncontrast cerebral MRI sequences, perfusion imaging was performed before and after the administration of intravenous acetazolamide. CVR was measured by comparing quantitative ASL brain perfusion before and after administration of intravenous acetazolamide. In order to validate and corroborate ASL-based whole brain and regional perfusion, phase-contrast (PC) imaging was also performed through the major neck vessels. FLAIR and susceptibility weighted sequences were performed to assess for white matter injury and microbleeds, respectively. Ten HIV-infected women and seven uninfected, age-matched controls were evaluated. Significant group differences were present in whole brain and regional CVR between HIV-infected and uninfected women. These regional differences were significant in the frontal lobe and basal ganglia. CVR measurements were not significantly impacted by the degree of white matter signal abnormality or presence of microbleeds. Despite complete viral suppression, dysfunction of the neurovascular unit persists in the HIV population. Given the lack of association between CVR and traditional imaging markers of small vessel disease, CVR quantification may provide an early biomarker of pre-morbid vascular disease.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Gânglios da Base/patologia , Artérias Cerebrais/patologia , Transtornos Cerebrovasculares/patologia , Lobo Frontal/patologia , Infecções por HIV/patologia , Substância Branca/patologia , Acetazolamida/administração & dosagem , Terapia Antirretroviral de Alta Atividade , Gânglios da Base/irrigação sanguínea , Gânglios da Base/diagnóstico por imagem , Gânglios da Base/virologia , Artérias Cerebrais/diagnóstico por imagem , Artérias Cerebrais/virologia , Transtornos Cerebrovasculares/complicações , Transtornos Cerebrovasculares/diagnóstico por imagem , Transtornos Cerebrovasculares/tratamento farmacológico , Estudos Transversais , Progressão da Doença , Feminino , Lobo Frontal/irrigação sanguínea , Lobo Frontal/diagnóstico por imagem , Lobo Frontal/virologia , HIV/efeitos dos fármacos , HIV/patogenicidade , Infecções por HIV/complicações , Infecções por HIV/diagnóstico por imagem , Infecções por HIV/tratamento farmacológico , Humanos , Angiografia por Ressonância Magnética/métodos , Pessoa de Meia-Idade , RNA Viral/genética , Marcadores de Spin , Substância Branca/irrigação sanguínea , Substância Branca/diagnóstico por imagem , Substância Branca/virologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA